initi
human
metapneumoviru
hmpv
isol
children
clinic
symptom
respiratori
syncyti
viru
rsv
infect
rsv
could
detect
sinc
numer
report
describ
detect
hmpv
clinic
specimen
children
adult
elderli
immunocompet
immunocompromis
patient
diagnos
acut
respiratori
ill
world
hmpv
associ
substanti
number
respiratori
tract
infect
otherwis
healthi
children
clinic
ill
similar
associ
common
respiratori
virus
serolog
survey
shown
hmpv
ubiquit
viru
infect
children
age
year
circul
human
least
year
hmpv
member
metapneumoviru
genu
paramyxovirida
famili
group
negativestrand
rna
virus
genet
studi
hmpv
demonstr
presenc
two
distinct
hmpv
serotyp
divid
two
subgroup
diagnosi
made
rtpcr
assay
respiratori
secret
rapid
antigen
detect
test
yet
avail
growth
cell
cultur
fastidi
vaccin
antibodi
monoclon
polyclon
chemotherapeut
agent
current
licens
use
prevent
treat
hmpv
infect
contribut
hmpv
pediatr
respiratori
tract
infect
suggest
import
develop
vaccin
viru
combin
develop
rsv
parainfluenza
virus
revers
genet
technolog
current
use
develop
multival
vaccin
hmpv
varieti
import
respiratori
virus
rsv
addit
research
defin
pathogenesi
viral
infect
host
specif
immun
respons
enhanc
knowledg
guid
search
prevent
therapeut
strategi
new
infecti
agent
human
metapneumoviru
hmpv
isol
nasopharyng
aspir
young
children
respiratori
tract
ill
netherland
initi
hmpv
isol
children
clinic
symptom
respiratori
syncyti
viru
rsv
infect
rsv
could
detect
sinc
numer
report
describ
detect
hmpv
clinic
specimen
children
adult
elderli
immunocompet
immunocompromis
patient
diagnos
acut
respiratori
tract
infect
rti
world
hmpv
envelop
viru
genom
singl
strand
rna
approxim
kb
genom
contain
eight
gene
presum
code
nine
differ
protein
genom
organ
hmpv
similar
ident
rsv
member
pneumoviru
contrast
pneumoviru
metapneumoviru
lack
gene
differ
posit
common
gene
ie
n
nucleocapsid
rna
bind
protein
p
phosphoprotein
matrix
protein
f
fusion
glycoprotein
l
major
polymeras
subunit
g
major
attach
protein
transcript
elong
rna
synthesi
regulatori
factor
sh
small
hydrophob
surfac
protein
absenc
open
read
frame
orf
f
gene
hmpv
viru
lack
gene
agreement
first
identifi
nonavian
member
metapneumoviru
genu
genet
analysi
n
p
f
gene
reveal
hmpv
show
higher
sequenc
homolog
metapneumoviru
genu
averag
compar
genu
pneumoviru
averag
basi
organ
viral
genom
sequenc
ident
metapneumoviru
avian
pneumoviru
also
known
turkey
rhinotrach
viru
hmpv
assign
member
metapneumoviru
genu
paramyxovirida
famili
metapneumoviru
pneumoviru
genera
two
genera
within
subfamili
pneumovirina
fig
pneumovirina
paramyxovirina
belong
paramyxovirida
famili
group
neg
strand
rna
virus
includ
sever
major
pathogen
human
anim
hmpv
infect
chicken
turkey
viru
unlik
zoonot
sourc
rtpcr
analys
use
primer
set
specif
paramyxovirus
parainfluenza
viru
mump
viru
measl
viru
rsv
simian
viru
type
sendai
viru
newcastl
diseas
viru
react
newli
identifi
hmpv
indic
close
genet
related
virus
hmpvspecif
antisera
react
immunofluoresc
assay
cell
infect
panel
paramyxovirus
orthomyxovirus
parainfluenza
virus
influenza
viru
b
rsv
although
genet
close
relat
hmpv
share
mani
biolog
properti
rsv
hmpv
isol
replic
slowli
tertiari
monkey
kidney
tmk
rhesu
monkey
kidney
cell
poorli
vero
cell
cell
could
propag
madin
darbi
canin
kidney
mdck
cell
chicken
embryo
fibroblast
cef
cytopath
effect
indistinguish
caus
rsv
although
occur
slightli
later
day
post
inocul
electron
microscopi
reveal
paramyxoviruslik
pleiomorph
particl
nm
short
envelop
project
nm
indistinguish
rsv
hmpv
chloroform
sensit
replic
optim
trypsindepend
manner
contrast
rsv
tmk
cell
hemagglutin
activ
turkey
chicken
guinea
pig
erythrocyt
display
combin
virolog
data
indic
hmpv
inde
member
paramyxovirida
famili
mode
transmiss
formal
studi
like
larg
particl
respiratori
secret
fomit
base
related
pneumovirus
nosocomi
transmiss
occur
warrant
contact
isol
scrupul
hand
wash
health
care
provid
genet
studi
hmpv
demonstr
presenc
two
distinct
hmpv
group
divid
two
subgroup
repres
strain
four
subgroup
subgroup
hmpv
subgroup
subgroup
hmpv
subgroup
nearli
complet
genom
sequenc
determin
prototyp
strain
hmpv
complet
genom
sequenc
determin
two
canadian
strain
studi
also
confirm
hmpv
gene
order
none
protein
identifi
character
direct
biochem
mean
function
still
need
confirm
bastien
colleagu
determin
complet
nucleotid
sequenc
n
p
f
gene
canadian
hmpv
isol
comparison
deduc
amino
acid
sequenc
n
f
gene
differ
isol
reveal
three
gene
well
conserv
ident
two
distinct
cluster
p
gene
show
divers
amino
acid
ident
isol
two
cluster
isol
within
cluster
canadian
cluster
isol
show
amino
acid
ident
isol
viral
protein
analyz
analysi
f
g
protein
gene
four
subgroup
show
f
protein
highli
conserv
demonstr
low
variabl
within
four
group
amino
acid
ident
subgroup
f
protein
becom
attract
princip
target
protect
antibodi
contrast
g
gene
show
high
sequenc
divers
furthermor
phylogenet
analys
show
hmpv
strain
obtain
differ
year
differ
countri
randomli
distribut
four
sublineag
address
antigen
relationship
differ
lineag
viru
neutral
assay
perform
show
differ
antigen
lineag
b
basi
result
propos
defin
two
main
lineag
hmpv
serotyp
b
although
serotyp
divid
two
genet
subgroup
subgroup
reflect
major
antigen
differ
character
extent
genet
divers
among
hmpv
strain
australia
worldwid
compar
nucleotideand
predict
amino
acidsequ
studi
perform
n
p
gene
comparison
align
sequenc
reveal
nucleotid
variat
divid
viral
strain
two
main
lineag
addit
two
distinct
subtyp
appar
within
lineag
defin
hmpv
type
variabl
p
gene
permit
reliabl
classif
hmpv
four
subtyp
indic
p
gene
valuabl
target
phylogenet
studi
confirm
classif
base
n
p
gene
agre
propos
studi
similar
sequenc
analys
avail
f
g
l
gene
sequenc
perform
lineag
found
thu
p
gene
seem
use
singl
target
genotyp
creation
global
classif
scheme
hmpv
larg
communitybas
phylogenet
studi
hmpv
surfac
glycoprotein
f
g
provid
evid
presenc
multipl
genotyp
within
subgroup
hmpv
evid
came
topolog
phylogenet
tree
bootstrap
valu
sequenc
arbitrarili
consid
genotyp
cluster
togeth
bootstrap
valu
result
nine
genotyp
six
possibl
genotyp
four
subgroup
togeth
strain
hmpv
group
may
cocircul
particular
year
shown
south
africa
time
four
subgroup
virus
detect
singl
year
limit
data
indic
hmpv
group
circul
singl
season
possibl
predomin
group
switch
success
season
agapov
et
al
show
furthermor
within
genotyp
f
n
gene
conserv
g
sh
gene
show
mark
variat
despit
genet
variabl
differ
sever
ill
caus
variou
hmpv
isol
note
contrast
recent
studi
suggest
genotyp
caus
sever
acut
rti
small
children
compar
genotyp
b
although
number
case
small
compar
studi
agapov
et
al
signific
differ
found
paramet
reflect
greater
sever
diagnosi
pneumonia
well
sever
index
combin
clinic
data
hypoxemia
intens
care
admiss
differ
result
might
relat
patient
group
studi
mani
studi
report
detect
hmpv
serogroup
predomin
serotyp
circul
isra
studi
hmpv
serogroup
also
highest
circul
rate
sequenc
sampl
four
subgroup
three
identifi
william
et
al
show
four
genet
lineag
hmpv
persist
last
year
commun
one
lineag
present
concurr
season
wherea
singl
lineag
domin
other
studi
lineag
common
wherea
lineag
seem
circul
period
contrast
other
studi
lineag
account
major
clinic
isol
might
due
primer
shown
less
sensit
detect
b
lineag
circul
multipl
lineag
chang
domin
group
viru
may
suggest
attempt
evas
preexist
immun
seen
also
rsv
studi
perform
differ
geograph
area
show
specif
strain
coexist
across
geograph
area
preliminari
evid
exist
hmpv
four
known
major
genet
lineag
hmpv
come
isol
hmpv
child
acut
asthma
exacerb
posit
pcr
result
obtain
use
primer
deriv
n
gene
amplifi
fragment
clone
plasmid
vector
sequenc
confirm
specif
pcr
although
nucleotid
sequenc
differ
significantli
repres
hmpv
strain
known
four
lineag
might
indic
heterogen
hmpv
higher
record
till
import
consequ
optim
rtpcr
protocol
hmpv
circul
human
least
year
seropreval
found
serum
sampl
obtain
individu
year
old
collect
netherland
appear
two
period
acquisit
hmpv
childhood
first
period
occur
within
first
year
life
second
period
occur
children
month
age
percentag
seroposit
children
increas
age
categori
children
year
age
seropreval
studi
children
japan
israel
show
seroposit
children
year
age
children
year
age
hmpvspecif
antibodi
netherland
seropreval
hmpv
children
reach
age
year
south
african
children
lower
seroposit
rate
observ
age
month
partial
explain
clearanc
maternalderiv
antibodi
month
onward
seroposit
rate
increas
children
age
month
seropreval
studi
indic
virtual
children
infect
earli
childhood
sinc
first
descript
hmpv
infect
children
van
den
hoogen
et
al
hmpv
found
part
world
tab
north
america
europ
asia
australia
viru
also
identifi
hivinfect
nonimmunocompromis
children
south
africa
hmpv
infect
account
least
rti
hospit
children
although
studi
report
much
higher
preval
tab
gener
commun
hmpv
infect
account
least
children
visit
gener
practition
outpati
clinic
rti
tab
rel
role
hmpv
respiratori
syndrom
adult
well
studi
larg
studi
patient
rti
diagnost
outcom
specimen
sent
specif
respiratori
pathogen
test
compar
rsv
detect
frequent
sampl
obtain
patient
rti
hmpv
secondmostdetect
viral
pathogen
found
sampl
isol
frequent
parainfluenza
virus
adenoviru
rhinoviru
influenza
virus
type
b
almost
prematur
infant
young
children
year
age
chronic
lung
diseas
congenit
heart
diseas
bueno
air
impact
hmpv
among
respiratori
virus
caus
rti
rsv
parainfluenza
viru
detect
respect
patient
group
spite
low
number
infect
caus
hmpv
sever
lung
diseas
seen
case
hmpv
isol
patient
sever
acut
respiratori
syndrom
sar
contribut
ill
remain
uncertain
experiment
anim
model
hmpv
infect
report
includ
primat
rodent
first
publish
experiment
hmpv
infect
model
cynomolgu
macaqu
macaca
fasciculari
confirm
hmpv
primari
pathogen
respiratori
tract
primat
hmpvinfect
macaqu
show
mild
clinic
sign
rhinorrhea
correspond
suppur
rhiniti
patholog
examin
addit
mild
eros
inflammatori
chang
mucosa
submucosa
conduct
airway
increas
number
alveolar
macrophag
bronchiol
pulmonari
alveoli
observ
close
associ
lesion
specif
express
hmpv
antigen
shown
immunohistochemistri
base
antigen
express
viral
replic
mainli
took
place
apic
surfac
ciliat
epitheli
cell
throughout
respiratori
tract
pharyng
excret
hmpv
show
peak
day
post
infect
pi
decreas
zero
day
concomit
reduct
number
infect
epitheli
cell
mild
upper
respiratori
tract
diseas
observ
macaqu
correspond
immunocompet
adult
due
fact
hmpv
replic
lower
respiratori
tract
cynomolgu
macaqu
sever
diseas
expect
immunocompromis
patient
investig
also
shown
hmpv
replic
lung
hamster
cotton
rat
without
produc
recogniz
clinic
sign
although
transient
histopatholog
pulmonari
chang
note
cotton
rat
hmpv
infect
smallanim
model
ferret
rabbit
report
induc
strong
immun
respons
level
viru
replic
anim
report
studi
respiratori
specimen
obtain
nasopharyng
aspir
common
respiratori
virus
neg
nasopharyng
aspir
nasal
swab
number
sampl
respiratori
specimen
obtain
nasopharyng
aspir
common
respiratori
virus
neg
nasopharyng
aspir
nasal
swab
skiadopoulo
et
al
extend
observ
show
member
hmpv
lineag
replic
effici
hamster
infect
induc
high
level
neutral
antibodi
resist
challeng
effect
homolog
heterolog
strain
addit
two
speci
nonhuman
primat
also
identifi
use
model
develop
respiratori
tract
diseas
chimpanze
viral
replic
african
green
monkey
chimpanze
develop
robust
immun
respons
although
level
viru
shed
low
protect
diseas
follow
rechalleng
either
strain
therefor
chimpanze
may
provid
use
nonhuman
primat
model
hmpv
diseas
less
ideal
studi
viru
replic
contrast
rhesu
macaqu
ideal
anim
model
quantit
hmpv
replic
although
develop
serum
neutral
antibodi
follow
hmpv
infect
hmpv
replic
effici
respiratori
tract
african
green
monkey
infect
anim
develop
high
level
hmpv
serumneutr
antibodi
effect
lineag
high
degre
genet
related
crossprotect
shown
mediat
immun
highli
conserv
f
protein
human
parainfluenza
viru
vector
bear
hmpv
f
protein
provid
protect
well
lineag
hmpv
indic
vector
might
use
vaccin
protect
diseas
caus
hmpv
balbc
mice
cotton
rat
consid
good
conveni
experiment
model
studi
pathogenesi
human
rsv
anoth
paramyxoviru
hmpv
balbc
mous
describ
conveni
anim
model
effici
viral
replic
signific
histopatholog
chang
lung
associ
system
respiratori
sign
larg
intranas
inocula
use
small
anim
experiment
model
hmpv
infect
balbc
mice
develop
studi
mechan
contribut
immun
diseas
pathogenesi
biphas
kinet
hmpv
replic
lung
tissu
shown
peak
titer
day
pi
viabl
viru
could
recov
lung
day
pi
genom
hmpvrna
detect
day
pi
lung
histopatholog
modest
character
mononuclear
cell
infiltr
interstitium
start
day
peak
day
decreas
day
pi
associ
bronchial
bronchiolar
inflamm
low
pulmonari
inflammatori
respons
may
contribut
persist
viru
hamelin
et
al
detect
infecti
viru
lung
balbc
mice
day
hmpv
infect
although
histopatholog
chang
still
signific
time
compar
shaminfect
mice
durat
sever
inflamm
around
alveoli
limit
cotton
rat
compar
balbc
mice
clinic
symptom
respiratori
distress
weight
loss
observ
day
pi
mice
infect
cotton
rat
recent
alvarez
tripp
report
hmpv
rna
could
still
detect
day
pi
lung
hmpvinfect
mice
persist
result
aberr
immun
respons
durat
pulmonari
inflamm
associ
singl
hmpv
challeng
character
consequ
viral
infect
respect
respiratori
function
evalu
hamelin
et
al
result
show
small
amount
viral
rna
still
present
lung
hmpvinfect
mice
least
day
pi
associ
signific
peribronchiol
perivascul
first
week
inflamm
mostli
consist
interstiti
inflamm
presenc
alveol
report
previous
time
inflamm
becam
character
promin
peribronchiolar
perivascular
infiltr
still
signific
day
increas
number
pasposit
cell
central
peripher
airway
day
pi
seen
suggest
increas
mucu
product
concurr
time
maxim
viral
replic
histopatholog
score
airway
obstruct
sever
follow
gradual
decreas
still
signific
day
pi
inflamm
seem
respons
chronic
obstruct
hyperrespons
airway
persist
month
result
reinforc
concept
sever
paramyxoviru
infect
earli
childhood
associ
develop
asthma
children
overal
data
suggest
balbc
mice
suscept
hmpv
infect
cotton
rat
basi
higher
viru
titer
level
lung
inflamm
combin
absenc
clinic
sign
absenc
clinic
sign
also
report
hamster
ferret
experiment
model
hmpv
infect
show
similar
pathogenesi
far
studi
rsv
infect
human
histopatholog
assess
hmpv
infect
lung
tissu
obtain
open
transbronchi
biopsi
five
immunocompromis
patient
show
acut
organ
lung
injuri
specif
area
diffus
alveolar
damag
hyalin
membran
format
foci
bronchiol
obliteransorgan
pneumonialik
reaction
seen
sampl
enlarg
type
ii
pneumocyt
smudg
hyperchromat
nuclei
resembl
smudg
cell
found
adenoviru
infect
detect
contrast
smudg
cell
detect
lung
tissu
sampl
four
patient
lower
rti
due
rsv
rhinoviru
parainfluenza
viru
might
characterist
histopatholog
pattern
hmpv
lower
rti
histopatholog
pattern
shown
studi
human
distinct
found
experiment
infect
nonhuman
primat
eros
inflammatori
chang
confin
conduct
airway
littl
known
natur
cytokin
respons
hmpv
human
peripher
blood
mononuclear
cell
cultur
stimul
hmpv
reveal
classic
cell
activ
depend
antigen
present
costimul
occur
compar
stimul
rsv
studi
use
balbc
mice
shown
indol
pulmonari
inflammatori
respons
character
minim
innat
immun
cell
traffick
lowlevel
interferon
ifn
express
induct
interleukin
il
express
later
infect
delay
cytotox
lymphocyt
ctl
activ
peak
express
macrophag
inflammatori
protein
ifn
rant
regul
upon
activ
normal
cell
express
secret
relat
sever
pulmonari
inflamm
balbc
mice
hmpv
weaker
induc
ifn
rsv
induc
higher
level
instead
look
cytokin
releas
respiratori
epitheli
surfac
hmpv
contrast
rsv
seem
poor
induc
elicit
ident
symptom
similar
sever
level
inflammatori
cytokin
tnf
respiratori
secret
infant
year
acut
rti
twoto
sixfold
lower
infect
hmpv
compar
rsv
higher
level
inhibit
differenti
combin
lower
level
ifninduc
hmpv
respons
weaker
antivir
respons
lead
lower
memori
cell
upon
viral
recal
mechan
underli
lifelong
typic
symptomat
reinfect
hmpv
rant
nasal
secret
children
year
admit
hospit
acut
expiratori
wheez
differ
report
infect
rsv
patient
rsv
infect
high
concentr
rant
vari
level
wherea
children
hmpv
infect
lower
concentr
rant
higher
level
seem
mechan
known
rsv
elicit
symptomat
diseas
infect
hmpv
mechan
may
includ
although
limit
direct
viral
damag
airway
vs
polar
pulmonari
immun
respons
lead
differ
clinic
symptom
chemokinemedi
inflamm
research
need
elucid
exact
mechan
ill
caus
hmpv
fusion
f
surfac
glycoprotein
identifi
major
crossprotect
antigen
addit
f
protein
subfamili
pneumovirina
paramyxovirus
also
separ
surfac
glycoprotein
involv
attach
call
g
protein
f
g
surfac
glycoprotein
signific
neutral
antigen
major
independ
protect
antigen
hmpv
virion
appear
three
surfac
glycoprotein
f
g
sh
protein
analyz
contribut
three
glycoprotein
neutral
protect
antibodi
hamster
immun
intranas
recombin
piv
type
express
glycoprotein
individu
ad
gene
f
glycoprotein
shown
major
contributor
induct
neutral
antibodi
protect
immun
g
sh
glycoprotein
induc
detect
neutral
antibodi
contribut
protect
minor
neglig
respect
contrast
paramyxovirus
includ
rsv
g
protein
stimul
high
level
neutral
protect
antibodi
cleavag
precursor
f
glycoprotein
prerequisit
infect
import
determin
virul
paramyxovirida
contribut
trypsindepend
cleavag
site
rqsr
hmpv
growth
vitro
well
known
requir
trypsin
vitro
rais
possibl
hmpv
virul
restrict
ineffici
cleavag
f
protein
use
recombin
hmpv
natur
occur
cleavag
sequenc
replac
sequenc
depend
upon
ad
trypsin
vitro
shown
replic
hamster
african
green
monkey
chang
result
suggest
cleavag
activ
major
determin
hmpv
virul
similar
result
report
other
use
point
mutat
f
gene
confer
intracellular
cleavabl
hmpv
hamster
model
four
princip
method
use
diagnosi
respiratori
viru
infect
viru
isol
cultur
antigen
detect
rna
dna
detect
serolog
studi
viru
easili
detect
viru
isol
laboratori
great
import
develop
rapid
sensit
reproduc
diagnost
test
identif
two
hmpv
serotyp
b
serotyp
divid
genet
sublineag
implic
develop
rtpcr
assay
serolog
diagnost
test
unavail
rapid
antigen
detect
test
fastidi
growth
cell
cultur
rtpcr
becom
method
choic
rtpcr
procedur
prove
sensit
viru
isol
detect
genet
distinct
hmpv
strain
cytopath
effect
variabl
rsvlike
syncytia
format
focal
round
cell
destruct
search
van
den
hoogen
et
al
cell
line
similar
suscept
four
hmpv
lineag
enhanc
detect
viru
cytopath
effect
result
gener
subclon
vero
cell
vero
cell
clone
cell
line
use
routin
viru
isol
netherland
commerci
avail
antibodi
yet
avail
monoclon
antibodi
mab
recogn
conserv
epitop
use
rapid
viral
diagnost
use
immunofluoresc
direct
techniqu
current
use
diagnos
rsv
confirm
hmpv
caus
cytopath
effect
achiev
rtpcr
test
viral
cultur
rtpcr
protocol
report
date
reli
amplif
l
n
f
gene
primer
sequenc
mainli
deriv
prototyp
strain
netherland
compar
evalu
rtpcr
assay
perform
lightcycl
instrument
detect
hmpv
infect
cell
cultur
show
posit
rate
use
primer
n
l
p
f
gene
second
evalu
studi
nasopharyng
aspir
posit
hmpv
n
gene
pcr
posit
rate
l
p
f
gene
respect
studi
conclud
rtpcr
assay
aim
amplifi
n
l
gene
code
two
intern
viral
protein
seem
conserv
region
genom
appear
particularli
suitabl
detect
hmpv
lineag
rapid
sensit
rtpcr
assay
n
gene
detect
limit
copi
develop
allow
rapid
amplif
detect
hmpv
sequenc
directli
clinic
sampl
h
howev
inadequ
primer
select
pcr
amplif
hmpv
detect
might
underestim
serolog
test
permit
retrospect
diagnosi
infect
almost
univers
childhood
seroconvers
fourfold
increas
antibodi
titer
must
demonstr
confirm
recent
infect
serolog
survey
perform
netherland
base
indirect
assay
use
hmpvinfect
cell
homemad
elisa
method
also
develop
use
cell
lysat
hmpv
conduct
larg
serolog
survey
simpler
elisa
test
use
viral
protein
possibl
deriv
two
serotyp
need
mab
use
diagnost
purpos
direct
whole
hmpv
protein
individu
protein
ishiguro
et
al
use
specif
antibodi
nucleocapsid
n
matrix
protein
serum
sampl
test
western
blot
use
recombin
n
protein
hmpv
express
escherichia
coli
result
indic
antibodi
n
protein
highli
specif
less
sensit
n
protein
protein
compar
immunofluoresc
antibodi
ifa
detect
whole
protein
hmpv
western
blot
analysi
use
recombin
p
protein
success
due
nonspecif
bind
human
sera
hmpv
ifaposit
sera
react
f
protein
hmpv
sdspage
signal
weak
suggest
probabl
direct
conformationaltyp
epitop
f
protein
antibodi
detect
hmpv
ifa
suspect
reaction
f
protein
author
develop
baculoviru
bac
express
hmpv
protein
ifa
show
sensit
hmpv
ifa
elisa
use
n
protein
hmpv
develop
recent
report
detect
adult
antibodi
n
protein
hmpv
previou
studi
adult
age
year
antibodi
detect
hmpv
ifa
bacf
ifa
bacf
ifa
studi
serum
sampl
japanes
subject
month
year
age
show
concord
result
convent
ifa
base
hmpvinfect
cell
titer
obtain
bacf
equal
higher
obtain
convent
ifa
bacf
ifa
studi
conclud
avail
larg
quantiti
bacexpress
hmpv
f
protein
offer
opportun
use
recombin
protein
diagnost
reagent
eia
ifa
immunoblot
studi
antigen
immunogen
characterist
f
protein
studi
like
import
urgent
need
abl
develop
hmpv
vaccin
near
futur
leung
et
al
use
vesicular
stomat
viru
infect
anim
seldom
human
produc
recombin
hmpv
f
protein
seroepidemiolog
studi
elisabas
system
mani
advantag
method
use
previou
studi
amount
hmpvspecif
antigen
standard
assay
antibodi
genotypespecif
viral
glycoprotein
measur
result
base
defin
criteria
rather
subject
determin
posit
result
ifa
two
rapid
antigen
detect
method
avail
ifa
test
elisa
studi
compar
rate
viru
detect
nasopharyng
secret
indirect
ifa
rtpcr
show
ifa
antihmpv
mous
mab
could
detect
hmpv
nasopharyng
secret
sensit
specif
compar
result
rtpcr
elisa
easier
perform
daili
clinic
practic
provid
result
object
ifa
immunofluoresc
stain
clinic
specimen
shell
vial
centrifug
cultur
svcc
method
commonli
use
clinic
virolog
laboratori
rapid
diagnosi
need
sensit
specif
mab
landri
et
al
evalu
hmpv
protein
util
rapid
diagnosi
hmpv
svcc
method
detect
hmpv
similar
svcc
stain
optim
day
post
inocul
abil
detect
posit
result
day
inocul
great
advantag
present
convent
cultur
method
use
stain
clinic
specimen
howev
success
due
nonspecif
background
stain
commerci
avail
chemicon
intern
temecula
ca
result
util
diagnosi
viral
rti
await
first
descript
hmpv
children
lower
rti
report
dutch
group
identifi
viru
respiratori
secret
clinic
symptom
similar
caus
rsv
rang
upper
rti
sever
bronchiol
pneumonia
winter
season
children
observ
year
age
year
old
asymptomat
carriag
seem
rare
children
hmpv
detect
infant
without
respiratori
symptom
preval
clinic
symptom
hmpvinfect
patient
identifi
rtpcr
respiratori
sampl
obtain
patient
univers
hospit
indic
preval
clinic
sever
due
hmpv
infect
slightli
lower
rsv
infect
winter
season
hmpvposit
patient
children
year
old
without
underli
ill
hmpv
found
significantli
less
frequent
rsv
children
month
old
hmpvposit
children
year
old
month
old
wherea
hrsvposit
children
year
old
also
month
old
other
found
mean
age
patient
infect
hmpv
slightli
lower
compar
rsv
hmpvposit
patient
year
old
diseas
eg
cystic
fibrosi
leukemia
nonhodgkin
lymphoma
recent
receiv
bone
marrow
kidney
transplant
indic
associ
immunosuppress
two
sever
immunocompromis
patient
die
due
progress
respiratori
failur
hmpv
sole
pathogen
detect
studi
involv
young
elderli
adult
hmpv
caus
sever
diseas
fragil
elderli
healthi
elderli
young
adult
clinic
symptom
children
year
age
n
due
hmpv
infect
includ
cough
rhiniti
fever
respiratori
distress
wheez
retract
specif
clinic
syndrom
caus
hmpv
seem
differ
caus
respiratori
virus
william
et
al
test
respiratori
specimen
period
us
previous
healthi
children
infect
due
hmpv
like
associ
bronchiol
less
like
associ
croup
infect
due
para
influenza
viru
hmpv
infect
less
like
associ
pneumonia
infect
rsv
influenza
viru
variou
studi
show
frequent
involv
hmpv
acut
bronchiol
infant
percentag
second
rsv
hmpv
associ
substanti
number
urti
episod
otherwis
healthi
outpati
children
clinic
ill
similar
associ
common
virus
includ
frequent
acut
otiti
media
studi
examin
role
hmpv
respect
exacerb
asthma
yield
conflict
result
two
studi
adult
patient
chronic
obstruct
pulmonari
diseas
copd
show
hmpv
could
detect
hospit
copd
patient
acut
exacerb
hmpv
detect
stabl
copd
patient
although
doubt
patient
asthmat
exacerb
hmpv
infect
whether
viru
associ
frequent
respiratori
virus
exacerb
yet
clear
remark
histori
asthma
famili
member
asthma
often
associ
hmpv
respect
rsv
respect
similar
season
suscept
popul
share
sever
respiratori
viral
infect
result
preval
coinfect
hmpv
respiratori
virus
might
lead
underestim
percentag
hmpvposit
sampl
identifi
studi
sampl
neg
respiratori
virus
test
see
also
tab
coinfect
rate
one
respiratori
virus
demonstr
sever
studi
search
caus
pathogen
rti
epidem
season
rsv
coincid
hmpv
potenti
exist
rsvhmpv
coinfect
sever
studi
identifi
case
lower
rti
evid
presenc
rsv
hmpv
detect
dual
infect
rsv
hmpv
frequent
infant
sever
diseas
ie
need
supplementari
oxygen
even
frequent
infant
sever
diseas
admit
intens
care
unit
mechan
ventil
foulongn
et
al
show
anoth
respiratori
viru
detect
hmpvposit
sampl
obtain
children
year
age
rti
one
coinfect
involv
rsv
durat
hospit
requir
supplement
oxygen
significantli
higher
hmpvrsv
coinfect
children
greensil
et
al
collect
nonbronchoscop
bronchoalveolar
sampl
infant
week
age
ventil
rsv
bronchiol
diagnos
antigen
test
detect
hmpv
perform
rtpcr
f
n
gene
infant
posit
rtpcr
rsv
bronchoalveolar
lavag
sampl
genom
hmpv
also
detect
high
rate
coinfect
rais
possibl
coinfect
rsv
hmpv
determin
diseas
sever
result
confirm
other
studi
associ
sever
bronchiol
dual
infect
rsv
hmpv
children
year
age
admit
hospit
coinfect
virus
confer
tenfold
increas
rel
risk
admiss
pediatr
intens
care
unit
mechan
ventil
high
case
incid
hmpv
infect
describ
associ
hospit
admiss
patient
sever
acut
respiratori
syndrom
hong
kong
contrast
other
found
similar
rate
bronchopneumonia
infant
infect
hmpv
alon
dual
infect
wilkesmann
et
al
find
lower
ill
sever
compar
hmpvinfect
children
match
rsvinfect
children
without
hmpv
coinfect
hand
season
distribut
hhmp
rsv
may
differ
specif
geograph
area
demonstr
studi
argentina
hong
kong
coinfect
infrequ
observ
peak
hmpv
countri
becom
preval
late
winter
earli
spring
like
develop
sensit
detect
method
dual
mix
infect
increasingli
recogn
necessarili
result
sever
infect
posit
rtpcr
test
result
differenti
activ
infect
prolong
shed
recent
acut
infect
termin
current
known
whether
hmpv
infect
lead
increas
suscept
secondari
bacteri
infect
absenc
sensit
tool
diagnos
bacteri
pneumonia
obstacl
defin
role
bacteri
coinfect
children
virusassoci
pneumonia
hypothesisgener
studi
involv
cohort
children
random
receiv
pneumococc
vaccin
placebo
children
test
presenc
hmpv
nest
rtpcr
admit
hospit
lower
rti
hivuninfect
hivinfect
children
incid
hmpvassoci
lower
rti
reduc
incid
clinic
pneumonia
reduc
data
combin
compar
find
respiratori
virus
suggest
respiratori
viral
infect
caus
hmpv
predispos
pneumococc
coinfect
bacterialvir
coinfect
import
pathogenesi
virusassoci
pneumonia
children
socioeconom
impact
hmpv
infect
children
household
well
known
report
household
contact
hmpvinfect
children
like
influenzainfect
children
fell
ill
significantli
frequent
requir
medic
visit
receiv
antipyret
prescript
also
absent
frequent
work
school
rsvinfect
children
find
suggest
hmpv
infect
children
consider
affect
famili
vaccin
antibodi
monoclon
polyclon
chemotherapeut
agent
current
licens
use
prevent
treat
hmpv
infect
howev
ribavirin
polyclon
antibodi
prepar
ivig
use
therapi
prevent
rsv
infect
children
known
broadspectrum
activ
inhibit
differ
virus
tissu
culturebas
assay
ribavarin
ivig
prepar
contain
high
titer
hmpvneutral
antibodi
found
inhibit
hmpv
replic
clinic
util
find
need
test
ulbrandt
et
al
describ
gener
panel
neutral
mab
bind
hmpv
f
protein
like
palivizumab
rsv
subset
antibodi
abil
neutral
prototyp
strain
b
hmpv
subgroup
vitro
two
antibodi
exhibit
highaffin
bind
f
protein
shown
protect
hamster
infect
hmpv
studi
far
shown
mab
f
protein
alon
protect
anim
viru
challeng
might
first
step
use
mab
prophylact
prevent
lower
rti
caus
hmpv
two
antibodi
found
mab
mab
characterist
compar
palivizumab
make
appeal
studi
despit
similar
structur
hmpv
rsv
f
protein
two
virus
share
amino
acid
sequenc
ident
consequ
antisera
gener
either
rsv
hmpv
neutral
across
pneumovirida
group
contribut
hmpv
pediatr
rti
suggest
import
develop
vaccin
viru
combin
develop
rsv
parainfluenza
virus
circul
two
serotyp
hmpv
might
implic
develop
vaccin
studi
cynomolg
macaqu
show
reinfect
suppress
high
titer
viru
neutral
antibodi
homolog
viru
far
less
heterolog
viru
neutral
antibodi
other
report
crossprotect
reciproc
crossneutr
studi
experiment
model
hmpv
infect
show
crossprotect
induc
high
level
consist
singl
serotyp
relev
test
import
genet
divers
whether
virus
one
genotyp
induc
greater
protect
homolog
viru
heterolog
one
although
difficult
assess
extent
crossprotect
import
estim
ultim
develop
monoval
bival
vaccin
formul
one
difficulti
assess
crossprotect
occurr
reinfect
viru
neutral
antibodi
titer
children
year
age
higher
year
age
suggest
reinfect
may
occur
frequent
discoveri
hmpv
sever
group
work
molecular
system
allow
gener
recombin
paramyxovirus
plasmid
dna
copi
viru
gene
viru
genom
similar
strategi
use
techniqu
refer
revers
genet
rapidli
employ
studi
replic
hmpv
gener
live
attenu
hmpv
vaccin
candid
foreign
gene
report
gene
green
fluoresc
protein
insert
hmpv
genom
express
effect
defin
transcript
start
gene
end
signal
revers
genet
use
rescu
strain
canada
netherland
entir
complementari
dna
cdna
virus
made
dna
copi
chimer
virus
made
use
antigen
protein
one
viru
insert
genom
anoth
viru
neutral
antibodi
respons
induc
chimer
viru
protect
host
challeng
hmpv
strain
macphail
et
al
identifi
smallanim
primat
model
evalu
vaccin
candid
kind
model
want
evalu
effect
safeti
vaccin
candid
also
futur
hmpv
antivir
drug
therapeut
prophylact
mab
result
show
syrian
golden
hamster
ferret
african
green
monkey
support
hmpv
replic
lower
upper
respiratori
tract
effici
result
high
level
hmpv
neutral
antibodi
recent
work
biacchesi
et
al
investig
function
sh
g
gene
develop
liveattenu
vaccin
previous
shown
delet
number
rsv
gene
sh
g
gene
deleteri
viru
rsv
mutant
evalu
primat
put
live
attenu
vaccin
candid
recov
recombin
hmpv
analyz
vitro
experiment
infect
hamster
delet
singl
gene
either
sh
g
show
similar
replic
wildtyp
viru
cell
cultur
mean
f
protein
alon
suffici
mediat
attach
fusion
cell
absenc
two
surfac
protein
addit
hmpv
g
sh
requir
effici
assembl
releas
progeni
viru
mutant
hmpv
strain
lack
sh
andor
g
gene
immunogen
highli
protect
hmpv
challeng
repres
promis
vaccin
candid
mutant
lack
g
g
shg
show
reduc
replic
contrast
mutant
lack
sh
gene
repres
promis
vaccin
candid
need
studi
nonhuman
primat
african
green
monkey
perform
follow
studi
group
experi
perform
recombin
hmpv
sh
g
gene
orf
delet
revers
genet
mutant
evalu
replic
vaccin
efficaci
follow
intranas
intratrach
administr
respiratori
tract
african
green
monkey
genedelet
viru
highli
immunogen
protect
wildtyp
hmpv
challeng
g
virus
show
markedli
reduc
replic
contrast
sh
viru
promis
vaccin
candid
appropri
clinic
evalu
delet
hmpv
protein
result
decreas
rna
replic
increas
gene
express
cell
cultur
consequ
might
mutant
provid
greater
antigen
synthesi
immunogen
vivo
tang
et
al
use
differ
approach
gener
hmpv
vaccin
candid
util
attenu
piv
type
vector
deliv
hmpv
f
protein
aim
induc
humor
cellular
immun
hmpv
infect
use
vector
new
use
develop
rsv
respiratori
pathogen
vaccin
candid
studi
chimer
bovinehuman
hmpv
shown
elicit
hmpvspecif
well
virusspecif
antibodi
cell
respons
african
green
monkey
bovinehuman
vector
hmpv
vaccin
might
therefor
function
bival
vaccin
immun
hmpv
infect
develop
bovinehuman
vectorbas
vaccin
express
f
protein
hmpv
rsv
provid
protect
three
respiratori
pathogen
caus
signific
diseas
young
children
howev
genet
stabil
vaccin
address
first
possibl
host
develop
immun
vector
matter
concern
especi
need
boost
primari
vaccin
recent
trial
young
infant
show
multipl
dose
attenu
result
inhibitori
vector
immun
interv
vaccin
time
appropri
epidemiolog
clinic
manifest
associ
hmpv
found
reminisc
rsv
sever
rti
occur
young
infant
elderli
subject
immunocompromis
host
season
distribut
resembl
rsv
influenza
viru
infect
recurr
epidem
winter
month
hmpv
second
import
caus
rsv
viral
lower
rti
children
hmpv
infect
account
least
rti
hospit
children
gener
commun
hmpv
infect
account
least
patient
visit
gener
practition
rti
interestingli
rate
detect
hmpv
gener
higher
retrospect
prospect
studi
observ
consist
select
bia
larger
prospect
studi
limit
typic
respiratori
viru
season
limit
test
respiratori
sampl
neg
respiratori
virus
use
appropri
control
need
conduct
diagnosi
made
rtpcr
assay
aim
amplifi
n
l
gene
addit
research
defin
pathogenesi
viral
infect
host
specif
immun
respons
enhanc
knowledg
guid
search
prevent
therapeut
strategi
develop
simpl
direct
assay
nasopharyng
sampl
near
futur
certainli
enhanc
understand
role
hmpv
rti
human
revers
genet
technolog
current
use
develop
multival
vaccin
hmpv
varieti
import
respiratori
virus
rsv
